Multiple myeloma (MM) is a cancer of plasma cells that has a varied response rate to treatment and a survival rate of 4-5 years. Poor survival has been attributed to drug resistance therefore identification of novel therapeutic targets for MM that overcome drug resistance is critical.
The MRC Career Development Awards, which are offered to support talented researchers to lead their own research, will enable Adam to build on his research interests in systems biology, immunology and epigenetics.
Specifically, he will develop novel, cost-effective multiplexed single-cell technologies that will provide an understanding of the relationship between the immune system and the MM tumour macroenvironment.
Commenting on his award Adam said: “I’m so pleased to have been offered the MRC award. We need to understand the cellular mechanisms that contribute to drug resistance within MM to be able to deliver better treatments. This award reinforces my belief that in time we will be able to expand the number of potential drug targets for MM, improving quality and longevity of life for patients.”
